Skip to Content

New Drug Approvals Archive - October 2016

See also: New Indications and Dosage Forms for October 2016

October 2016

Carnexiv (carbamazepine) Injection

Date of Approval: October 7, 2016
Company: Lundbeck Inc.
Treatment for: Seizures

Marketing Status: Discontinued

Carnexiv (carbamazepine) is an intravenous injection formulation of the antiepileptic drug carbamazepine indicated as short-term replacement therapy for oral carbamazepine when oral administration is temporarily not feasible.

Lartruvo (olaratumab) Injection

Date of Approval: October 19, 2016
Company: Eli Lilly and Company
Treatment for: Soft Tissue Sarcoma

Lartruvo (olaratumab) is a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody indicated in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma (STS).

Zinplava (bezlotoxumab) Injection

Date of Approval: October 21, 2016
Company: Merck & Co., Inc.
Treatment for: Prevention of Clostridium Difficile Infection Recurrence

Zinplava (bezlotoxumab) is a selective, fully-human, monoclonal antibody that binds to Clostridium difficile toxin B, indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older.

New Drug Approvals Archive

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.